Maxim Group set a $1.00 target price on BioLineRx Ltd. (NASDAQ:BLRX) in a research note issued to investors on Tuesday morning. The firm currently has a hold rating on the stock.

Several other brokerages have also commented on BLRX. Roth Capital reaffirmed a buy rating and issued a $7.00 price objective on shares of BioLineRx in a research report on Monday, September 26th. Zacks Investment Research lowered shares of BioLineRx from a buy rating to a hold rating in a research report on Tuesday, October 11th. Finally, S&P Equity Research lowered their price objective on shares of BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $2.68.

Shares of BioLineRx (NASDAQ:BLRX) traded down 2.73% on Tuesday, hitting $1.07. 26,717 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $1.07 and its 200 day moving average is $0.94. The firm’s market cap is $60.37 million. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.63.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, November 22nd. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01. On average, equities analysts predict that BioLineRx will post ($0.26) earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the stock. KCG Holdings Inc. boosted its position in shares of BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock valued at $174,000 after buying an additional 121,650 shares in the last quarter. Morgan Stanley boosted its position in BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares in the last quarter. Finally, Senvest Management LLC boosted its position in BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares in the last quarter. 14.35% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “BioLineRx Ltd. (BLRX) Given a $1.00 Price Target at Maxim Group” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/23/biolinerx-ltd-blrx-given-a-1-00-price-target-at-maxim-group.html.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.